Effectiveness of Riboflavin-Moxifloxacin Amniotic Membrane as an Adjuvant for PACK-CXL in Moderate to Severe Infectious Keratitis

Inclusion Criteria: * Patients diagnosed with moderate-to-severe infectious corneal ulcers (bacterial or fungal origin) by the Infection and Immunology subdivision at Dr. Sardjito General Hospital, Yogyakarta * Patients scheduled to undergo Photo-Activated Chromophore Keratitis-Corneal Cross-linking (PACK-CXL) therapy * Patients aged 18 years and older * Patients willing to undergo PACK-CXL therapy * Patients capable of providing informed consent and willing to participate in the entire study protocol Exclusion Criteria: * Patients who refuse follow-up examinations (tear film collection, corneal staining, or corneal scans) after the PACK-CXL procedure * Patients with damaged or insufficient clinical specimens (e.g., tear samples) for laboratory analysis * Patients unable to commit to the follow-up schedule